Treatment of cervical cancer in 2024 in the highlight of KEYNOTE-A18 study

Professor Remi Nout shares his thoughts on the treatment of cervical cancer in 2024 in the light of KEYNOTE-A18 study.

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

Professor Remi Nout shares his thoughts on the interim results of the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial that were presented during the ESMO Congress 2024.

Breast cancer, early stage highlights of the ESMO 2024 Congress

Professor Ann Partridge shares his thoughts on breast cancer, early stage highlights of the ESMO 2024 Congress.

Setting a new benchmark for ALK+ aNSCLC targeted therapy - report from ESMO2024

Professor Tony S.K. Mok shares his thoughts on setting a new benchmark for ALK+ aNSCLC targeted therapy.

POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC - report from ESMO2024

Professor Dominik P. Modest shares his thoughts on POD1UM-303/InterAACT 2 study, which are potentially practice-changing findings in squamous cell carcinoma of the anal canal.

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC.

PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer

Professor Silke Gillessen presented new results from the PEACE-3 trial at the 2024 ESMO conference. This study indicates that combining Enzalutamide with Radium223 significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases over Enzalutamide alone.

Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

Professor Silke Gillessen discussing results from STAMPEDE trial assessing the addition of metformin to ADT for patients with mHSPC.